NPDES Pretreatment Discharge Requirements for GSK-Hamilton Pharmaceuticals in Montana
The GSK-Hamilton facility is a campus with buildings that support pharmaceutical manufacturing of MPL and QS-21 adjuvants. These adjuvants are shipped offsite to other GSK locations for vaccine formulation. The GSK-Hamilton facility is owned by Corixa Corporation dba GlaxoSmithKline Vaccines. GSK is authorized under the Pretreatment Notice of Discharge Requirements, MT-PF00103 to discharge the wastewaters generated from these manufacturing processes and treated to the City of Hamilton’s publicly owned treatment works (POTW). Authorization for discharge in the draft documents is limited to only those outfalls specifically listed in the notice of discharge requirements.